| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
Licoflavonol targets the type three secretion system (T3SS) of Salmonella enterica serovar Typhimurium. The T3SS is a virulence factor that allows bacteria to inject effector proteins into host cells. Licoflavonol inhibits the secretion of SPI-1 effector proteins by regulating the transcription of the SicA/InvF genes and the transportation of the effector protein SipC. By targeting this virulence system, licoflavonol reduces the pathogenicity of Salmonella without killing the bacteria, which may exert less selective pressure for resistance.
|
|---|---|
| ln Vitro |
In vitro, licoflavonol demonstrates a strong inhibitory effect on the secretion of SPI-1 effector proteins by Salmonella enterica serovar Typhimurium. It regulates the transcription of the SicA/InvF genes and inhibits the transportation of the effector protein SipC. It also exhibits antioxidant and anti-inflammatory activities. These in vitro activities confirm its potential as an anti-virulence agent.
|
| ln Vivo |
Detailed in vivo activity data for licoflavonol are not extensively provided in the search results. However, its ability to inhibit the T3SS of Salmonella suggests potential for in vivo efficacy in reducing Salmonella infection and its associated pathology. Further studies in animal models of Salmonella infection are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
Non-cell-based assays for licoflavonol are not typical, as its mechanism involves the inhibition of bacterial secretion systems. However, its antioxidant activity can be measured using assays such as DPPH radical scavenging.
|
| Cell Assay |
Cellular assays for licoflavonol are performed using Salmonella enterica serovar Typhimurium cultures. The bacteria are grown in the presence of licoflavonol, and the secretion of effector proteins (e.g., SipC, SipB) into the culture supernatant is measured by Western blotting. The transcription of T3SS-related genes (e.g., SicA, InvF) is measured by qPCR. These assays confirm the compound's inhibitory effect on the T3SS.
|
| Animal Protocol |
In vivo animal models for licoflavonol would likely involve the use of mice infected with Salmonella enterica serovar Typhimurium. The compound would be administered, and its effects on bacterial load, tissue damage, and survival would be measured. These studies are crucial for evaluating the compound's potential as an anti-virulence therapeutic.
|
| ADME/Pharmacokinetics |
Licoflavonol has a molecular weight of 354.35 g/mol and a molecular formula of C20H18O6. It is a flavonoid that is soluble in DMSO. It has a purity of ≥98%. Detailed PK parameters such as half-life and bioavailability are not extensively detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for licoflavonol are not provided in the search results. As a natural product, it is generally considered to have a good safety profile, but thorough toxicological studies would be required for therapeutic development. The compound is intended for research use only and is not for human consumption.
|
| References |
|
| Additional Infomation |
Licoflavonol is a type of flavonoid compound. It has been reported to exist in plants of the genera Glycyrrhiza (uralensis), Glycyrrhiza, and other organisms with relevant data. See also: Glycyrrhiza glabra (genus Glycyrrhiza).
Licoflavonol is a flavonoid from licorice root. It is a novel natural inhibitor of the Salmonella T3SS. It inhibits the secretion of SPI-1 effector proteins by regulating SicA/InvF gene transcription and SipC transportation. It also has antioxidant and anti-inflammatory properties. It has the CAS number 60197-60-6 and is supplied for research purposes. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.3533
|
| Exact Mass |
354.11
|
| Elemental Analysis |
C, 67.79; H, 5.12; O, 27.09
|
| CAS # |
60197-60-6
|
| PubChem CID |
5481964
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
608.3±55.0 °C at 760 mmHg
|
| Melting Point |
185 - 187 °C
|
| Flash Point |
220.2±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.700
|
| LogP |
4.15
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
597
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2C([H])=C([H])C(=C([H])C=2[H])O[H])=C(C(C2C(=C(C(=C([H])C1=2)O[H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O[H])=O)O[H]
|
| InChi Key |
TVMHBSODLWMMMV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-10(2)3-8-13-14(22)9-15-16(17(13)23)18(24)19(25)20(26-15)11-4-6-12(21)7-5-11/h3-7,9,21-23,25H,8H2,1-2H3
|
| Chemical Name |
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
